Changing the composition of the microbiome, the multitude of bacteria, fungi, protozoa and viruses that reside in or on our bodies, or the way the microbiome interacts with its human host, could lead to novel therapeutic approaches to disease. Inflammatory bowel disorders, Clostridia-associated diarrhea and obesity are all potential targets for microbiome altering medicines.
The microbiome, an infographic
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.
Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.
